6
Oct
2022

Nobel for Bertozzi, Red Tree Eyes West Coast, & Doubling Down on Singapore

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Parabilis IPO Pops, J&J Buys More Degraders, & GSK’s Precision Oncology Bet
RevMed’s Moment in the Sun, In Vivo CAR-Ts Shine & NewLimit’s Healthspan Haul
Vaccines Get a Boost, Apogee Hunts Down Dupixent, GSK Raises the Bar in HepB
Lilly’s Triple-G Delivers, Parabilis Eyes IPO, & Regeneron’s LAG-3 Whiff